Drug Targets – News and Features

To find out more about AI in pharma, Technology Networks spoke with Roger Palframan, head of US Research and digital for Early Solutions at UCB.

In this interview, Dr. Jason Park, co-founder and CEO of Empress Therapeutics, tells us more about the Chemilogics platform and the benefits this approach to drug discovery can offer.

An interdisciplinary team of researchers investigated how cell cycle flexibility allows tumor cells to escape the effect of anti-cancer drugs that target cell division.

Generative AI like ChatGPT can do more than help write emails — it can also design new drugs to treat disease, reports a new study that shows how AI can generate unique molecular structures as potential drugs.

A potential new drug to prevent Alzheimer’s disease in people with the so-called Alzheimer’s gene has been discovered by a University of Arkansas for Medical Sciences.

A promising drug could lead to a new treatment for the most aggressive form of breast cancer, which affects thousands of women each year. A pre-clinical study found the new drug successfully inhibits the growth of triple negative breast cancer.

A combination of two cancer drugs could be effective against malignant peripheral nerve sheath tumors (MPNSTs), soft tissue tumors that are stubbornly resistant to chemotherapy and radiation.

A drug designed to slow or halt progression of a specific type of heart failure – transthyretin amyloid cardiomyopathy – has been shown to be safe and effective in a phase 3 trial.

Scripps Research scientists developed a compound that can block a protein previously considered challenging to drug and is implicated in autoimmune diseases, including lupus..

The efficacy of a drug candidate not only depends on the drug–target binding affinity, but also on the binding kinetics. This article outlines why studying drug binding kinetics is important in drug discovery, covering key approaches to measure the drug–target kinetics.